Document Detail


Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
MedLine Citation:
PMID:  19298641     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Secondary hyperparathyroidism (SHPT) is common among haemodialysis patients. Intensive treatment with calcitriol is often complicated by hypercalcaemia, hyperphosphataemia and elevated calcium phosphorus (Ca X PO(4)) product. Paricalcitol is a vitamin D analogue developed to overcome some of the limitations of calcitriol therapy. The study objectives were to compare the response of intact parathyroid hormone (iPTH) and the incidence of hypercalcaemia, hyperphosphataemia and elevated Ca X PO(4) product in patients with severe SHPT treated with either i.v. calcitriol or i.v. paricalcitol. METHODS: This was a single centre randomized open label study. Patients with serum intact iPTH of 50 pmol/L or more were randomized to receive either i.v. calcitriol (0.01 ug/kg) or i.v. paricalcitol (0.04 ug/kg) during every haemodialysis treatment. Serum iPTH, calcium, phosphorus and alkaline phosphatase were measured at the beginning of the study and every 3 weeks for 12 weeks. RESULTS: Twenty-five patients were enrolled into the study - 12 were randomized into the calcitriol group and 13 into the paricalcitol group. There were no differences in the baseline study parameters between both groups. Serum iPTH levels were significantly reduced (P = 0.003) only in the paricalcitol group but not in the calcitriol group (P = 0.101). On the other hand, serum calcium levels were significantly increased only in the calcitriol group (P = 0.004 vs P = 0.242). Serum phosphorus, alkaline phosphatase and Ca X PO(4) product were not different. CONCLUSION: Intravenous paricalcitol may be superior to i.v. calcitriol for the treatment of severe SHPT in our chronic haemodialysis population. A larger randomized controlled trial is indicated to confirm these initial findings.
Authors:
Abdul Halim Abdul Gafor; Rashidi Saidin; Chee Yean Loo; Rozita Mohd; Soehardy Zainudin; Shamsul Azhar Shah; Kong Chiew Tong Norella
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2009-03-10
Journal Detail:
Title:  Nephrology (Carlton, Vic.)     Volume:  14     ISSN:  1440-1797     ISO Abbreviation:  Nephrology (Carlton)     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-13     Completed Date:  2009-10-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9615568     Medline TA:  Nephrology (Carlton)     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  488-92     Citation Subset:  IM    
Affiliation:
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. halimgafor@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Calcitriol / administration & dosage*,  adverse effects
Calcium / blood
Ergocalciferols / administration & dosage*,  adverse effects
Female
Humans
Hyperparathyroidism, Secondary / blood,  drug therapy*
Injections, Intravenous
Male
Middle Aged
Phosphates / blood
Renal Dialysis*
Chemical
Reg. No./Substance:
0/Ergocalciferols; 0/Phosphates; 131918-61-1/paricalcitol; 32222-06-3/Calcitriol; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of activin A on tubulointerstitial fibrosis in diabetic nephropathy.
Next Document:  Histopathological changes and tumour necrosis factor-alpha, transforming growth factor-beta and tena...